Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis
Clinical and Translational Oncology · 06.06.2026 · 28 (11) · 5306-5319
DOI: 10.1007/s12094-026-04434-1 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Translational Oncology, online erschienen am 06.06.2026. Verfasst von Asayel M Alsultan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Kuwait Institute for Medical Specializations, Kuwait City, Kuwait. Hauptthemen laut MEDLINE: Atrial Fibrillation, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Atrial fibrillation (AF) may represent an important component of cardiac toxicity after thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). However, the available evidence remains limited and heterogeneous. METHODS: We conducted a systematic review and meta-analysis of observational studies evaluating AF after thoracic radiotherapy in NSCLC. PubMed, Scopus, Web of Science, Embase, and Cochrane Central were searched from inception to March 2026. The primary outcome was pooled new-onset AF. A separate exploratory analysis evaluated cumulative incidence of AF at reported follow-up intervals using random-effects models. RESULTS: Nine retrospective cohort studies were included in the systematic review, and eight were eligible for quantitative synthesis. Six of the eight studies contributed to the primary analysis, whereas two did not report the primary outcome in a directly comparable format, including 4410 patients and 736 events. The pooled proportion of new-onset AF was 0.14 (95%CI 0.07-0.24), with substantial heterogeneity (I2 = 94.0%). Three studies contributed to the cumulative-incidence analysis, although the pooled estimate was highly imprecise (0.09, 95% CI, 0.00-0.84; I2 = 0.0%). Across studies, AF risk appeared to be associated with radiation exposure to cardiac substructures, particularly the sinoatrial node, pulmonary veins, and atrial structures. CONCLUSION: AF may represent a clinically relevant component of cardiac toxicity after thoracic radiotherapy in NSCLC, but the current evidence remains limited by retrospective study design and marked heterogeneity, underscoring the need for prospective validation and standardized outcome reporting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kuwait Institute for Medical Specializations, Kuwait City, Kuwait.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Royal College of Surgeons in Ireland, Bahrain, Muharraq, Kingdom of Bahrain.
- College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain. Dr_Alharran@outlook.com.
Zitieren
APA
Alsultan, A. M., AlAbdulaaly, R. A., Alyahya, S. A., Alajmi, L., Alsubaiei, A. A., Gadelmawla, A. F., Alkhan, F., Alrubaiaan, M., Burashed, K. K., Noman, M., Bawa, Y., Alharran, A. M., & Alfehaid, A. (2026). Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Clinical and Translational Oncology, 28(11), 5306-5319. https://doi.org/10.1007/s12094-026-04434-1
Vancouver
Alsultan AM, AlAbdulaaly RA, Alyahya SA, Alajmi L, Alsubaiei AA, Gadelmawla AF, et al. Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Clinical and Translational Oncology. 2026;28(11):5306-5319. doi:10.1007/s12094-026-04434-1
BibTeX
@article{Alsultan2026,
author = {Alsultan, Asayel M and AlAbdulaaly, Reman A and Alyahya, Saud A and Alajmi, Lojain and Alsubaiei, Amal A and Gadelmawla, Ahmed Farid and Alkhan, Fouz and Alrubaiaan, Moudhi and Burashed, Khulood K and Noman, Malak and Bawa, Yasmine and Alharran, Abdullah M and Alfehaid, Abdullatif},
title = {Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis},
journal = {Clinical and Translational Oncology},
year = {2026},
volume = {28},
number = {11},
pages = {5306--5319},
doi = {10.1007/s12094-026-04434-1}
}
EUVIMED